Sidney Kimmel Cancer Center at Jefferson | Strategic Alliance Partners

The National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center – Jefferson Health (SKCC) is a nationally recognized center for practice-changing discovery and comprehensive cancer treatment, offering a depth and breadth of experience in all aspects of cancer from the laboratory to the clinic. Our mission is to improve the lives of cancer patients and their families through compassion, innovation, and breakthrough discoveries. For more information, visit sidneykimmelcancercenter.jeffersonhealth.org.

Connect with us:

Latest from Sidney Kimmel Cancer Center at Jefferson


Dr. Gomella on the Evolution of AR Inhibitors in Prostate Cancer

March 19, 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.

Dr. Gomella on the Prevalence of Genetic Testing in Prostate Cancer

April 19, 2019

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the prevalence of genetic testing in prostate cancer.

Gomella Calls for Increased Genetic Testing in Prostate Cancer

April 18, 2019

Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.

Sidney Kimmel Cancer Center at Jefferson Joins Global Network

September 10, 2018

The Sidney Kimmel Cancer Center – Jefferson Health announces a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which launched today in the United States and China.

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

July 13, 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Dr. Trabulsi Discusses Postoperative Radiation in Prostate Cancer

May 23, 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.